Patent application number | Description | Published |
20090124543 | ACTIVITY DEPENDENT NEUROTROPHIC FACTOR III (ADNF III) - The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) β-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease. | 05-14-2009 |
20090137469 | Use of ADNF polypeptides for treating peripheral neurotoxicity - This invention relates to the use of ADNF polypeptides in the treatment of neurotoxicity induced by chemical agents or by disease processes. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites. | 05-28-2009 |
20090170780 | PROTECTION OF THE RETINA AGAINST LASER INJURY BY NAP AND RELATED PEPTIDES - This invention relates to the use of ADNF polypeptides in the treatment of laser-induced retinal damage and related conditions. | 07-02-2009 |
20100216723 | NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS - This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease. | 08-26-2010 |
20100303785 | NOVEL THERAPEUTICS BASED ON TAU/MICROTUBULE DYNAMICS - The invention is based on the discovery of a novel neuroprotective peptide. In addition, the invention rests on the discovery that the NAP peptide enhances the association of tau and the brain-specific beta tubulin subunit. In addition, NAP modifies microtubule assembly and dynamics, in part, by affecting the tyrosination of microtubule proteins. The invention provides compositions and methods for treatment and prevention of neuronal disorders, including NAP-binding and tau-binding agents, tau peptide mimetics, NAP-like and NAP-like tau peptide mimetics. | 12-02-2010 |
20120010148 | COMBINATION THERAPIES USING NAP - This invention relates to treatment of neurodegeneration, multiple sclerosis, or schizophrenia using an ADNF III polypeptide in combination with another therapeutic agent. Neurodegeneration, including neurodegeneration caused by dementia-related conditions, such as tauopathies, including Alzheimer's disease, and aging-related dementia, is treated by a combination of an ADNF III polypeptide and an acetylcholinesterase inhibitor. Multiple sclerosis is treated by a combination of an ADNF III polypeptide and glatiramer acetate. Schizophrenia is treated with a combination of an ADNF III peptide and an antipsychotic drug, selected from Aripiprazole, Clozapine, Ziprasidone, Resperidone, Quetiapine, and Olanzapine. | 01-12-2012 |
20120015878 | USE OF ADNF POLYPEPTIDES FOR TREATING ANXIETY AND DEPRESSION - This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions. | 01-19-2012 |
20120208763 | NAP ALPHA-AMINOISOBUTYRIC ACID ANALOG WITH NEUROPROTECTIVE ACTIVITY - The invention relates to compositions and methods to confer protection on neurons. Peptides derived from the NAPVSIPQ (SEQ ID NO:4) peptide and including branched amino acids, such as alpha-aminoisobutyric acid, are included. Also included are methods of preventing and treating neurodegenerative disorders and damage caused by neurotoxic substances. | 08-16-2012 |
20130053320 | TREATMENT OF ANEMIA BY ADNP AND ADNF POLYPEPTIDES - This invention relates to the use of ADNP, ADNP2, and ADNF polypeptides in the treatment of anemia and related conditions. Compositions of the ADNP, ADNP2, or ADNF polypeptides for such use are disclosed. Also provided are methods for concentrating or extracting ADNP, ADNP2, or ADNF polypeptides from dairy products and the use of dairy products in the context of treating anemia. | 02-28-2013 |
20130123186 | NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS - This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease. | 05-16-2013 |
20130164743 | METHOD FOR DIAGNOSING AND MONITORING SCHIZOPHRENIA AND TAUOPATHIES - The present invention provides methods and kits for diagnosing or monitoring conditions such as schizophrenia and tauopathies in a patient by determining the level of ADNP1 or ADNP2 in a sample from the patient. | 06-27-2013 |